Literature DB >> 16247460

Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma.

A B Gladden1, R Woolery, P Aggarwal, M A Wasik, J A Diehl.   

Abstract

Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by overexpression of cyclin D1 due to the t(11;14) chromosomal translocation. While expression of cyclin D1 correlates with MCL development, expression of wild-type (WT) cyclin D1 transgene in murine lymphocytes is unable to drive B-cell lymphoma. As cyclin D1 mutants that are refractory to nuclear export display heighten oncogenicity in vitro compared with WT D1, we generated mice expressing FLAG-D1/T286A, a constitutively nuclear mutant, under the control of the immunoglobulin enhancer, Emu. D1/T286A transgenic mice universally develop a mature B-cell lymphoma. Expression of D1/T286A in B lymphocytes results in S phase entry in resting lymphocytes and increased apoptosis in spleens of young premalignant mice. Lymphoma onset correlates with perturbations in p53/MDM2/p19Arf expression and with BcL-2 overexpression suggesting that alterations in one or both of these pathways may contribute to lymphoma development. Our results describe a cyclin D1-driven model of B-cell lymphomagenesis and provide evidence that nuclear-retention of cyclin D1 is oncogenic in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16247460      PMCID: PMC2832762          DOI: 10.1038/sj.onc.1209147

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

Review 1.  Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.

Authors:  M Hall; G Peters
Journal:  Adv Cancer Res       Date:  1996       Impact factor: 6.242

2.  Mantle cell lymphoma: a clinicopathologic study of 80 cases.

Authors:  L H Argatoff; J M Connors; R J Klasa; D E Horsman; R D Gascoyne
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

Review 3.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

4.  Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.

Authors:  J A Diehl; F Zindy; C J Sherr
Journal:  Genes Dev       Date:  1997-04-15       Impact factor: 11.361

5.  New functional activities for the p21 family of CDK inhibitors.

Authors:  J LaBaer; M D Garrett; L F Stevenson; J M Slingerland; C Sandhu; H S Chou; A Fattaey; E Harlow
Journal:  Genes Dev       Date:  1997-04-01       Impact factor: 11.361

6.  A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase.

Authors:  J A Diehl; C J Sherr
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

7.  Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

Authors:  F Bosch; A López-Guillermo; E Campo; J M Ribera; E Conde; M A Piris; T Vallespí; S Woessner; E Montserrat
Journal:  Cancer       Date:  1998-02-01       Impact factor: 6.860

8.  Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E.

Authors:  Y Sofer-Levi; D Resnitzky
Journal:  Oncogene       Date:  1996-12-05       Impact factor: 9.867

9.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.

Authors:  F Zindy; C M Eischen; D H Randle; T Kamijo; J L Cleveland; C J Sherr; M F Roussel
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

10.  Oncogenic collaboration of the cyclin D1 (PRAD1, bcl-1) gene with a mutated p53 and an activated ras oncogene in neoplastic transformation.

Authors:  K Uchimaru; K Endo; H Fujinuma; L Zukerberg; A Arnold; T Motokura
Journal:  Jpn J Cancer Res       Date:  1996-05
View more
  65 in total

1.  Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia.

Authors:  Daphne de Jong; Siegfried Janz
Journal:  J Pathol       Date:  2010-07       Impact factor: 7.996

Review 2.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

3.  Mouse models of cancer as biological filters for complex genomic data.

Authors:  Elisa Oricchio; Andrew L Wolfe; Jonathan H Schatz; Konstantinos J Mavrakis; Hans-Guido Wendel
Journal:  Dis Model Mech       Date:  2010-09-27       Impact factor: 5.758

4.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

Review 5.  In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation?

Authors:  Jonathan D Moore
Journal:  Nat Rev Cancer       Date:  2013-02-07       Impact factor: 60.716

Review 6.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

7.  FISH is more sensitive than Southern analysis at identifying increased levels of cyclin D1 gene amplified in breast cancer cell lines.

Authors:  Nie Dongsong; Jian Y Zhou
Journal:  Mol Biol Rep       Date:  2009-12-05       Impact factor: 2.316

Review 8.  The rb pathway and cancer therapeutics.

Authors:  W Du; J S Searle
Journal:  Curr Drug Targets       Date:  2009-07       Impact factor: 3.465

9.  Impaired nuclear export of tumor-derived c-terminal truncated cyclin D1 mutant in ESCC cancer.

Authors:  Meili Hao; Xiangmei Chen; Ting Zhang; Tao Shen; Qing Xie; Xiujuan Xing; Hongxi Gu; Fengmin Lu
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

10.  Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

Authors:  Sílvia Beà; Itziar Salaverria; Lluís Armengol; Magda Pinyol; Verónica Fernández; Elena M Hartmann; Pedro Jares; Virginia Amador; Luís Hernández; Alba Navarro; German Ott; Andreas Rosenwald; Xavier Estivill; Elias Campo
Journal:  Blood       Date:  2008-11-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.